Permeability of the blood –brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis

Annals of Neurology, EarlyView.

Source: Annals of Neurology - May 12, 2018 Category: Neurology Authors: Stig P.CramerMD, PhD , Helle J.SimonsenBMS , AravinthanVaratharajBMBCh , IanGaleaMD, PhD , Jette L.FrederiksenMD, DMSc , Henrik B. W.LarssonMD, DMSc Source Type: research